ClinicalTrials.gg
RecruitingNCT05910944STOP iNPHUpdated Apr 30, 2026

European Study of Prodromal iNPH

An observational study in Normal Pressure Hydrocephalus and Hydrocephalus, sponsored by Johan Virhammar. Recruiting at 7 sites in 3 countries. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Johan Virhammar · Observational

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
140
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Hydrocephalus, Normal Pressure with a site in Sweden — 1 open to participants now, 2 under way, none of them phase 3. Hydrocephalus, Normal Pressure · Sweden.

Started
2023
the only one that year
Observational
7 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Johan Virhammar

Among the 14 studies in Hydrocephalus, Normal Pressure with a site in Sweden, this one is the only one that started in 2023, is one of 7 observational ones, and was the 14th registered.

Hydrocephalus, Normal Pressure

78 studies on the registry are indexed under Hydrocephalus, Normal Pressure; 20 are open to participants now.

Browse Hydrocephalus, Normal Pressure studies →

Open to participants now

1 of the 14 studies in Hydrocephalus, Normal Pressure with a site in Sweden is open now.

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 16 Hydrocephalus, Normal Pressure studies recruiting now, 12 (75%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hydrocephalus, Normal Pressure with a site in Sweden, or all of them as a file.
02

Study summary

To investigate if progression from prodromal into symptomatic NPH can be predicted from advanced neuroimaging, biomarkers in cerebrospinal fluid (CSF) and plasma and investigate the unknown mechanisms causing deterioration by investigating longitudinal changes in the above-mentioned variables. Three different cohorts with both asymptomatic and symptomatic patients as well as healthy controls will be investigated over time, both without intervention and before and after shunt surgery.

Read the detailed description

Three prospective cohorts will be included during five years from seven European centers.

Group 1 - Prodromal NPH. Patients with imaging features associated with iNPH and no symptoms, or to little symptoms to motivate shunt surgery, will be included prospectively. At baseline, an MRI of the brain will be performed and a lumbar puncture to collect CSF as well as blood samples. The patients will be followed with a standardized scheme that will go on for as long as the patient chose to remain in the study or until the patient develops symptoms and are referred for shunt surgery. The study scheme includes repeated assessments of symptoms, MRI of the brain, CSF samples and blood samples. The following study visits are planned before surgery: baseline, 6 months, 1st year, 2nd year, 4th year, 6th year. After shunt surgery, clinical evaluations and blood samples will be collected at four assessments during five years post-operative.

Group 2 - Healthy controls - For every patient in Group 1, one patient can be included in Group 2. They will be investigated with the same protocol as Group 1 but only follow the protocol for one cycle (Baseline to year 4).

Group 3 - Symptomatic NPH - For each included individual in Group 1 (prodromal NPH), two patients are included in Group 3 (symptomatic NPH). These patients are consecutively included at each centre from routine patients that are planned for shunt surgery. They should be age matched with the individual in Group 1 (+/- 3 years). Their investigations will be identical with the post-operative routine for five years as Group 1.

03

Conditions studied

  • Normal Pressure Hydrocephalus
  • Hydrocephalus

Keywords

  • natural history
  • cerebrospinal fluid
  • biomarkers
  • long term follow-up
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients in Group 1 can be included from patients referred to a tertiary hydrocephalus center after investigations/work-up have shown too mild symptoms to motivate shunt surgery.

Healthy age-matched controls (Group 2) can be included by advertising and by asking relatives to patients in Group 1 and Group 3.

For each included individual in Group 1 (prodromal iNPH), two patients are included in Group 3 (symptomatic iNPH). These patients are consecutively included at each center from routine patients that are planned for shunt surgery. They should be age matched with the individual in Group 1 (+/- 3 years).

Eligibility criteria

Inclusion criteria - Group 1 - prodromal iNPH

  • Brain imaging with both:

    • Evans index > 0.3
    • Callosal angle ≤ 90 º or:
    • Disproportionately enlarged subarachnoid space hydrocephalus (DESH) - defined as: enlarged ventricles, dilated sylvian fissures and tight sulci at the high convexity.
  • Absence of symptoms or too mild symptoms to motivate shunt surgery according to local routine, and all of the following:

    • Normal gait pattern, or slight disturbance of the gait pattern that is not considered to be caused by a disease in the central nervous system (CNS).
    • Gait velocity (maximum gait speed), men ≥ 1.4 m/s; women ≥ 1.25 m/s.
    • Rombergs test with eyes open > 60 seconds
    • (MMSE) ≥ 27 or Montreal Cognitive Assessment (MoCA) ≥ 23

Exclusion criteria - Group 1 - prodromal iNPH

  • for MRI
  • Other serious disease with expected survival less than three years
  • Other type of hydrocephalus:

    • non-communicating hydrocephalus
    • secondary communicating hydrocephalus
    • suspected congenital hydrocephalus (severely enlarged ventricles, narrow sylvian fissures and normal non-compressed sulci at the high convexity or morphological findings consistent with PaVM18)
  • Anticoagulants in a dose that hinders lumbar puncture

Inclusion criteria - Group 2 - healthy controls

  • Age > 65 years

Exclusion criteria - Group 2 - healthy controls:

  • Imaging findings meet inclusion criteria of Group 1
  • Previously known relevant neurological disease
  • Pathological gait pattern with unknown reason.
  • MMSE \< 27 or MoCA \< 26.
  • Anticoagulants in a dose that hinders lumbar puncture

Inclusion criteria Group 3 symptomatic iNPH

  • iNPH diagnosis according to international guidelines.19
  • Age matched with the individual in Group 1 (+/- 3 years)

Exclusion criteria Group 3 symptomatic iNPH

  • Previous stroke (clinical stroke, not only radiologically verified)
  • Other serious disease with expected survival less than three years
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
140 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 1 - prodromal iNPH

    Individuals with typical imaging findings consistent with iNPH but none or too mild symptoms to motivate shunt surgery.

    Procedure: Shunt surgery

  • Group 2 - Healthy controls

    Age matched healthy controls

  • Group 3 - symptomatic iNPH

    Patients with symptomatic iNPH

    Procedure: Shunt surgery

Interventions

  • ProcedureShunt surgery

    Shunt surgery according to each local centers routine

06

What researchers measure

Primary outcomes

  1. Frequency of patients with prodromal iNPH that requires shunt surgery within 6 years from inclusion.

    Symptoms are assessed with the idiopathic Normal Pressure Hydrocephalus scale (iNPH-scale) with addition of the gait tests: 10 meter walking in maximum speed, timed up and go test (TUG) and 3 m walking backwards. Each center decides when symptoms have progressed enough to motivate shunt surgery according to local traditions and routine. Low values in time and steps of the gait tests indicate good performance and high values of the iNPH-scale (range: 0-100) indicates good performance.

    Time frame: From date of inclusion until decision of shunt surgery, assessed up to 72 months

  2. Frequency of patients with prodromal iNPH that progress to symptomatic iNPH

    Symptoms are assessed with the iNPH-scale with addition of the gait tests: 10 meter walking in maximum speed, timed up and go test (TUG) and 3 m walking backwards. A patient is considered symptomatic when total iNPH-scale is reduced by at least 20 points or the mean speed of the gait tests are reduced by 20%. Low values in time and steps of the gait tests indicate good performance and high values of the iNPH-scale (range: 0-100) indicates good performance.

    Time frame: From date of inclusion until 20 points reduction in total iNPH-scale score or 20% reduction in gait speed, assessed up to 72 months

  3. Post operative improvement in iNPH-scale score in patients with mild, moderate and severe preoperative symptoms

    Differences in short (3 and 12 months) and long-term outcome (36 and 60 months) measured as change between preoperative and postoperative iNPH-scale score will be compared between patients with mild, moderate and severe preoperative symptoms. High values of the iNPH-scale (range: 0-100) indicates good performance.

    Time frame: Change from preoperative (last visit before surgery) iNPH scale at 3 months, 12 months, 36 months and 60 months follow-up.

Secondary outcomes

  1. Change in white matter hyperintensities (WMH)

    Assess change in volume (mL) of white matter hyperintensities (WMH) measured with volumetric magnetic resonance imaging (MRI) and calculate associations between change in WMH and change in symptoms.

    Time frame: Change from baseline at 24 months, at 48 months and at time of decision of shunt surgery, assessed up to 72 months

  2. Change in brain morphology

    Assess change in brain morphology assessed with the idiopathic Normal Pressure Hydrocephalus (iNPH) Radscale and calculate associations between change in iNPH Radscale and change in symptoms.

    Time frame: Change from baseline at 24 months, at 48 months and at time of decision of shunt surgery, assessed up to 72 months

  3. Change in ventricular volume

    Assess change in ventricular volume (mL) measured with volumetric magnetic resonance imaging (MRI) and calculate associations between change in ventricular volume and change in symptoms.

    Time frame: Change from baseline at 24 months, at 48 months and at time of decision of shunt surgery, assessed up to 72 months

  4. Change in parenchymal water content

    Assess change in parenchymal water content (mL) measured with Synthetic MR and calculate associations between change in parenchymal water and change in symptoms.

    Time frame: Change from baseline at 24 months, at 48 months and at time of decision of shunt surgery, assessed up to 72 months

  5. Change in cerebral myelin volume

    Assess change in cerebral myelin volume (mL) measured with Synthetic MR and calculate associations between change in cerebral myelin volume and change in symptoms.

    Time frame: Change from baseline at 24 months, at 48 months and at time of decision of shunt surgery, assessed up to 72 months

  6. Changes in plasma biomarkers

    Change in plasma levels of neurofilament light chain protein (ng/L), Total-tau (ng/L), amyloid beta-42 (ng/L), glial fibrillary acidic protein (ng/L) will be measured using Quanterix (SIMOA).

    Time frame: Change from baseline at 6 months, 12 months, 24 months, 48 months and at time of decision of shunt surgery, assessed up to 72 months

  7. Changes in cerebrospinal fluid (CSF) biomarkers

    Change in CSF levels of neurofilament light chain protein (ng/L), Total-tau (ng/L), amyloid beta-42 (ng/L), glial fibrillary acidic protein (ng/L) will be measured using Quanterix (SIMOA).

    Time frame: Change from baseline at 6 months, 12 months, 24 months, 48 months and at time of decision of shunt surgery, assessed up to 72 months

  8. Changes in plasma and cerebrospinal fluid (CSF) proteins

    Semi-quantified levels of approximately 200 proteins are measured with proximity extension assay (Neurology panel and Neuro exploratory panel, Olink.com). Measured semi-quantitative in the unit NPX.

    Time frame: Change from baseline at 6 months, 12 months, 24 months, 48 months and at time of decision of shunt surgery, assessed up to 72 months

  9. Change in quality of life

    Quality of life assessed by EQ-5D-5L (EuroQoL 5 Dimensions 5 Levels). A self-assessment questionnaire with five different aspects of quality of life scored on five-level scales.

    Time frame: Change from baseline at 6 months, 12 months, 24 months, 48 months and at time of decision of shunt surgery, assessed up to 72 months

07

Study locations

2 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Dec 2035, 145 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2023
First posted
Jun 20, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Dec 31, 2035
CompletionEst.
Dec 31, 2035
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05910944
Lead sponsor
Johan Virhammar
Collaborators
Swedish Society for Medical Research
Responsible party
Johan Virhammar (Associate professor, Uppsala University Hospital) — Sponsor-investigator
First posted
Jun 20, 2023
Start date
Nov 1, 2023
Primary completion
Dec 31, 2035 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Apr 30, 2026

Study contacts

Johan Virhammar, MD, PhD
Contact
johan.virhammar@neuro.uu.se
+46186110000
Johan Virhammar, MD, PhD
principal investigator · Uppsala University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion